BiotechTube

IPH2101

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoldering Multiple Myeloma

Conditions

Smoldering Multiple Myeloma

Trial Timeline

Sep 1, 2010 → Jan 1, 2013

NCT ID
NCT01222286

About IPH2101

IPH2101 is a phase 2 stage product being developed by Innate Pharma for Smoldering Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT01222286. Target conditions include Smoldering Multiple Myeloma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT01222286Phase 2Completed
NCT00999830Phase 2Completed
NCT01256073Phase 1Completed

Competing Products

13 competing products in Smoldering Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
Elotuzumab (BMS-901608; HuLuc63)AbbViePhase 2
52
BHQ880NovartisPhase 2
52
carfilzomib + Lenalidomide + Dexamethasone + MelphalanAmgenPhase 2
51
DenosumabAmgenPhase 2
51
Carfilzomib + Lenalidomide + Daratumumab + DexamethasoneAmgenPhase 2
51
ElranatamabPfizerPhase 2
51
Nivolumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Elotuzumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Dexamethasone + Iberdomide HydrochlorideBristol Myers SquibbPhase 2
51
LinvoseltamabRegeneron PharmaceuticalsPhase 2
51
Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3
76
SelinexorKaryopharm TherapeuticsPhase 2
44
PD-L1 peptideIO BiotechPhase 2
44

Other Products from Innate Pharma

IPH2101Phase 2
44
IPH5201 + durvalumab + standard chemotherapyPhase 2
44
IPH4102Phase 2
44
avdoralimabPhase 2
44
Lacutamab + Gemcitabine + OxaliplatinePhase 2
44